Biohaven Pharmaceutical shares surge after Pfizer agrees to acquire company

CNBC's Jim Cramer and the 'Squawk on the Street' team break down shares of Biohaven Pharmaceuticals after drug giant Pfizer agreed to acquire the company for $11.6 billion.